Business Description
![Astellas Pharma Inc Astellas Pharma Inc logo](https://static.gurufocus.com/logos/0C00000Y91.png?14)
Astellas Pharma Inc
ISIN : US04623U1025
Share Class Description:
ALPMY: ADRDescription
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.4 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | 4.83 | |||||
Interest Coverage | 1.23 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.63 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.8 | |||||
3-Year EBITDA Growth Rate | -3 | |||||
3-Year EPS without NRI Growth Rate | -55.4 | |||||
3-Year FCF Growth Rate | -26 | |||||
3-Year Book Growth Rate | 6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 122.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.2 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 63.69 | |||||
9-Day RSI | 56.87 | |||||
14-Day RSI | 53.31 | |||||
6-1 Month Momentum % | -17.98 | |||||
12-1 Month Momentum % | -34.74 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.93 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.28 | |||||
Days Inventory | 265.3 | |||||
Days Sales Outstanding | 109.67 | |||||
Days Payable | 190.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 4.67 | |||||
Dividend Payout Ratio | 16.03 | |||||
3-Year Dividend Growth Rate | 18.6 | |||||
Forward Dividend Yield % | 4.67 | |||||
5-Year Yield-on-Cost % | 8.76 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | -17.49 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.76 | |||||
Operating Margin % | 0.92 | |||||
Net Margin % | 0.81 | |||||
FCF Margin % | 5.54 | |||||
ROE % | 0.82 | |||||
ROA % | 0.41 | |||||
ROIC % | 0.32 | |||||
ROC (Joel Greenblatt) % | 10.71 | |||||
ROCE % | 1.58 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 223.31 | |||||
PE Ratio without NRI | 537.53 | |||||
Shiller PE Ratio | 19.7 | |||||
Price-to-Owner-Earnings | 196.88 | |||||
PS Ratio | 1.78 | |||||
PB Ratio | 1.79 | |||||
Price-to-Free-Cash-Flow | 31.81 | |||||
Price-to-Operating-Cash-Flow | 16.6 | |||||
EV-to-EBIT | 103.75 | |||||
EV-to-Forward-EBIT | 11.4 | |||||
EV-to-EBITDA | 17.87 | |||||
EV-to-Forward-EBITDA | 9.11 | |||||
EV-to-Revenue | 2.12 | |||||
EV-to-Forward-Revenue | 2.31 | |||||
EV-to-FCF | 37.86 | |||||
Price-to-Projected-FCF | 0.92 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | 0.96 | |||||
FCF Yield % | 3.16 | |||||
Forward Rate of Return (Yacktman) % | -2.39 |